诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09969 诺诚健华

休市中 12-19 16:08:06

13.540

+0.360

+2.73%

最高13.820	最低13.110	成交量1,529万
今开13.190	昨收13.180	日振幅5.39%
总市值238.57亿	流通市值202.29亿	总股本17.62亿
成交额2.07亿	换手率1.02%	流通股本14.94亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":13.54,"timestamp":1766131686008,"preClose":13.18,"halted":0,"volume":15286955,"delay":0,"floatShares":1494000000,"shares":1762000000,"eps":-0.28773004225384996,"marketStatus":"休市中","change":0.36,"latestTime":"12-19 16:08:06","open":13.19,"high":13.82,"low":13.11,"amount":207099661,"amplitude":0.053869,"askPrice":13.54,"askSize":336000,"bidPrice":13.49,"bidSize":54000,"shortable":3,"etf":0,"ttmEps":-0.15769376961924847,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766367000000},"marketStatusCode":7,"adr":0,"listingDate":1584892800000,"exchange":"SEHK","adjPreClose":13.18,"openAndCloseTimeList":[[1766107800000,1766116800000],[1766120400000,1766131200000]],"volumeRatio":2.5200230906268057,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":22.2,"timestamp":1766127600000,"preClose":22,"halted":0,"volume":6582600,"delay":0,"premium":"-44.89"}},"requestUrl":"/m/hq/s/09969","defaultTab":"news","newsList":[{"id":"2592134408","title":"港股异动 | 诺诚健华(09969)涨超4% 自研新型TYK2抑制剂ICP-332治疗CSU获批准开展II/III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2592134408","media":"智通财经","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592134408?lang=zh_cn&edition=full","pubTime":"2025-12-19 11:17","pubTimestamp":1766114258,"startTime":"0","endTime":"0","summary":"消息面上，12月18日，据诺诚健华官微消息，公司宣布，自主研发的新型TYK2抑制剂soficitinib治疗慢性自发性荨麻疹获国家药品监督管理局药品审评中心批准开展II/III期临床试验。Soficitinib是诺诚健华自主研发的高效、高选择性的新型口服TYK2抑制剂，开发用于治疗多种T细胞相关的自身免疫性疾病，目前开发的适应症深度布局皮肤科这一广阔的市场，包括特应性皮炎、白癜风、结节性痒疹、荨麻疹等。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","688428","BK4134","III","BK1161","09969","BK0239"],"gpt_icon":0},{"id":"2592044139","title":"医药股集体走高 药明生物(02269)涨5.93% 机构料明年板块稳中向好态势延续","url":"https://stock-news.laohu8.com/highlight/detail?id=2592044139","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592044139?lang=zh_cn&edition=full","pubTime":"2025-12-19 10:23","pubTimestamp":1766111038,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药股集体走高，药明生物 涨5.93%，药明合联涨4.56%，君实生物涨4.54%，康诺亚-B涨4.19%，荣昌生物涨3.98%，科伦博泰生物-B涨4.00%，泰格医药涨4.30%，复宏汉霖涨3.72%，诺诚健华涨3.26%。交银国际发布医药行业周报，展望2026年，该机构认为板块稳中向好态势延续，但影响市场表现的核心因素或呈分化态势，后续选股逻辑或将重回基本面和估值，即关注存在基本面预期差、当前仍被低估的个股。","market":"other","thumbnail":"https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971870","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417516902.SGD","LU1969619763.USD","02696","LU0348735423.USD","LU0326950275.SGD","LU0856984785.SGD","02269","LU0181495838.USD","BK1161","LU0516422366.SGD","09995","02268","BK1141","LU0196878994.USD","SG9999002562.SGD","BK1576","LU0051755006.USD","LU0417516738.SGD","LU0823426308.USD","LU2488822045.USD","LU1242518931.SGD","01877","02162","159938","LU0359201612.USD","LU0572944931.SGD","LU1880383366.USD","LU1688375341.USD","LU2328871848.SGD","LU0708995583.HKD","BK1587","LU0039217434.USD","LU0348825331.USD","BK1610","03347","LU0052750758.USD","LU0819121731.USD","06990","LU0823426480.USD","LU0359202008.SGD","BK1521","BK1574","LU0588546209.SGD","LU1242518857.USD","09939","IE00B0JY6N72.USD","HK0000165453.HKD","09969","SG9999014674.SGD","LU0327786744.USD"],"gpt_icon":0},{"id":"2592201369","title":"奥布替尼SLE临床试验突破背后 诺诚健华单产品依赖隐忧｜创新药观察","url":"https://stock-news.laohu8.com/highlight/detail?id=2592201369","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592201369?lang=zh_cn&edition=full","pubTime":"2025-12-18 15:03","pubTimestamp":1766041380,"startTime":"0","endTime":"0","summary":"12月15日，生物医药公司诺诚健华宣布，其核心产品奥布替尼用于治疗系统性红斑狼疮（SLE）的IIb期临床研究达到主要终点，并已获国家药品监督管理局批准开展Ⅲ期临床试验。这一进展虽标志着该药在开拓自身免疫疾病这一巨大新市场的道路上迈出关键一步，但其通往成功商业化的道路仍布满不确定性，或将面临来自临床试验、市场竞争及公司战略的多重严峻挑战。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512183595356395.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512183595356395.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","09969","BK1161","688428","SLE","BK4077","BK0239","159992","06978"],"gpt_icon":0},{"id":"2592986219","title":"每日卖空追踪 | 诺诚健华 12月17日卖空量成交19.1万股，卖空比例为4.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592986219","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592986219?lang=zh_cn&edition=full","pubTime":"2025-12-17 16:30","pubTimestamp":1765960242,"startTime":"0","endTime":"0","summary":"诺诚健华北京时间12月17日，涨0.15%，卖空量成交19.1万股，较上一交易日减少85.75%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217163658a45615d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217163658a45615d7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","09969"],"gpt_icon":0},{"id":"2592998675","title":"美国投行分析师看好奥布替尼治疗多发性硬化的差异化优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2592998675","media":"同壁财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592998675?lang=zh_cn&edition=full","pubTime":"2025-12-17 11:48","pubTimestamp":1765943331,"startTime":"0","endTime":"0","summary":"美国投行H.C. Wainwright分析师Matthew Caufield 给予诺诚健华合作伙伴zenas biopharma “买入”评级，理由是Zenas正在研发BTK抑制剂奥布替尼在治疗进展型多发性硬化症  方面展现出良好的前景。Caufield认为 ，凭借独特的药代动力学特征和关键性试验设计，奥布替尼依然具有差异化优势。此外，每天一次75毫克奥布替尼剂量组的疗效优于每天一次50毫克剂量组，这表明疗效呈剂量依赖性的改善趋势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217115411a45516ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217115411a45516ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","09969"],"gpt_icon":0},{"id":"2591097566","title":"12月16日诺诚健华跌6.09%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2591097566","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591097566?lang=zh_cn&edition=full","pubTime":"2025-12-16 15:36","pubTimestamp":1765870568,"startTime":"0","endTime":"0","summary":"证券之星消息，12月16日诺诚健华跌6.09%，收盘报22.5元，换手率2.81%，成交量7.55万手，成交额1.72亿元。重仓诺诚健华的前十大公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共30家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为34.91亿元，最新净值3.1742，较上一交易日下跌3.71%，近一年上涨34.53%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600020122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","BK1161","BK1574","BK0239","09969"],"gpt_icon":0},{"id":"2591565672","title":"创新药概念再度走低 诺诚健华(09969.HK)跌超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591565672","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591565672?lang=zh_cn&edition=full","pubTime":"2025-12-16 11:21","pubTimestamp":1765855266,"startTime":"0","endTime":"0","summary":"每经AI快讯，创新药概念股再度走低，截至发稿，诺诚健华(09969.HK)跌5.09%，报12.86港元；石药集团(01093.HK)跌3.99%，报7.21港元；信达生物(01801.HK)跌3.36%，报79港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512163592831521.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512163592831521.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","688428","09969","06978","BK1574","BK0239","BK1161"],"gpt_icon":0},{"id":"2591644571","title":"诺诚健华：截至2025年11月28日A股股东户数约1.79万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2591644571","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591644571?lang=zh_cn&edition=full","pubTime":"2025-12-15 21:43","pubTimestamp":1765806180,"startTime":"0","endTime":"0","summary":"证券日报网讯12月15日，诺诚健华在互动平台回答投资者提问时表示，截至2025年11月28日公司A股股东户数约为1.79万户。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512153592007823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["399300","159982","09969","BK1574","688428","BK1161","BK0239"],"gpt_icon":0},{"id":"2591620772","title":"每日卖空追踪 | 诺诚健华 12月15日卖空量成交41.9万股，卖空比例为5.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591620772","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591620772?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:30","pubTimestamp":1765787441,"startTime":"0","endTime":"0","summary":"诺诚健华北京时间12月15日，跌5.05%，卖空量成交41.9万股，较上一交易日减少72.79%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163649a44d43e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163649a44d43e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","09969"],"gpt_icon":0},{"id":"2591665068","title":"诺诚健华(688428.SH)：奥布替尼治疗系统性红斑狼疮IIb期研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2591665068","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591665068?lang=zh_cn&edition=full","pubTime":"2025-12-14 16:27","pubTimestamp":1765700828,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(688428.SH)公告，公司自主研发的BTK抑制剂奥布替尼治疗系统性红斑狼疮(简称“SLE”)的IIb期临床研究达到主要终点，并获国家药品监督管理局(NMPA)药品审评中心(CDE)批准开展III期注册性临床试验。公司将尽快启动该临床研究。临床IIb结果展示，在接受治疗48周的患者中，奥布替尼展现了卓越的有效性、良好的耐受性和安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688428","BK1574","09969","BK1161","BK0239"],"gpt_icon":0},{"id":"2590257886","title":"港股诺诚健华涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590257886","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590257886?lang=zh_cn&edition=full","pubTime":"2025-12-12 14:21","pubTimestamp":1765520510,"startTime":"0","endTime":"0","summary":"每经AI快讯，诺诚健华(09969.HK)涨超3%，截至发稿，涨3.24%，报14港元，成交额5105.45万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512123590068918.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512123590068918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688428","BK1574","09969","BK1161","BK0239"],"gpt_icon":0},{"id":"2591687883","title":"近期，齐鲁制药、诺诚健华等在抗肿瘤药方面好消息频现！","url":"https://stock-news.laohu8.com/highlight/detail?id=2591687883","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591687883?lang=zh_cn&edition=full","pubTime":"2025-12-12 14:11","pubTimestamp":1765519893,"startTime":"0","endTime":"0","summary":"近些年来，中国抗肿瘤药物市场销售一直呈现稳步增长趋势。随着老龄化及公众癌症预防意识的持续提高，抗肿瘤药物市场规模还在不断上涨，业内预计到2029年，中国抗肿瘤药物行业市场规模有望达到5590亿元。近期，就有不少药企在新药临床、上市方面传来好消息。其通过瘤内注射，具有抑制肿瘤生长的功能。总的来说，2025年中国在抗肿瘤药方面的不断突破，是近年来医药行业转型升级的集中体现。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212141533a44414c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212141533a44414c0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1574","BK1161","01477","09969"],"gpt_icon":0},{"id":"2590520907","title":"港股异动 | 诺诚健华(09969)涨超3% 预计不久将递交佐来曲替尼治疗儿童患者新药上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2590520907","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590520907?lang=zh_cn&edition=full","pubTime":"2025-12-12 14:05","pubTimestamp":1765519550,"startTime":"0","endTime":"0","summary":"消息面上，12月11日，诺诚健发布公告，国家药品监督管理局已批准第二代小分子泛原肌球蛋白相关激酶抑制剂佐来曲替尼，用于治疗携带NTRK融合基因的成人和12岁以上青少年实体瘤患者。佐来曲替尼已被NMPA纳入“星光计划”，该计划是一项为鼓励儿童抗肿瘤药物研发而开展的试点项目。本公司预计不久将递交佐来曲替尼治疗儿童患者的新药上市申请。NTRK融合基因存在于各种类型的肿瘤，目前已在超过26种实体瘤中发现了NTRK融合基因。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380803.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","BK1574","BK0239","688428","09969"],"gpt_icon":0},{"id":"2590475925","title":"港股早知道 | 国际银价续创新高；汇丰：预计美联储明后两年不会降息；云顶新耀与海森生物达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2590475925","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590475925?lang=zh_cn&edition=full","pubTime":"2025-12-12 09:00","pubTimestamp":1765501238,"startTime":"0","endTime":"0","summary":"此前美联储政策制定者以分化的表决结果将利率下调了25个基点。云顶新耀宣布与海森生物达成战略合作，发挥商业化平台的优势与布局2025年12月11日，港股创新药企云顶新耀宣布，其全资附属公司云顶新耀医药科技有限公司已与海森生物医药有限公司签署两项战略合作协议：商业化服务协议以及授权许可协议。本次增持后，朱江明及傅利泉与所属的单一最大股东集团合共持有公司2.09亿股H股及1.29亿股内资股，占公司已发行总股数的23.75%。","market":"hk","thumbnail":"https://static.tigerbbs.com/38508134c6853c521e764dc952e7334a","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/38508134c6853c521e764dc952e7334a"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380662.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","BK1147","IE00BZ08YT58.USD","01952","06099","09863","BK1515","BK1191","BK1183","BK1521","BK1574","IE00BZ08YS42.EUR","09969","HK0000165453.HKD","IE00BZ08YR35.GBP","01177","02670","BK1564","BK1583","BK1119","BK1161"],"gpt_icon":0},{"id":"2590359020","title":"每日卖空追踪 | 诺诚健华 12月11日卖空量成交22万股，卖空比例为6.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590359020","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590359020?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:30","pubTimestamp":1765441840,"startTime":"0","endTime":"0","summary":"诺诚健华北京时间12月11日，涨0.15%，卖空量成交22万股，较上一交易日减少77.62%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211163756979c69b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211163756979c69b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","09969"],"gpt_icon":0},{"id":"2590902245","title":"诺诚健华12月11日获主力加仓77.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590902245","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590902245?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:16","pubTimestamp":1765440962,"startTime":"0","endTime":"0","summary":"12月11日, 诺诚健华股价涨0.15%，报收13.58元，成交金额4591.1万元，换手率0.23%，振幅3.39%，量比0.60。诺诚健华今日主力资金净流入77.4万元，上一交易日主力净流入352.7万元。该股近5个交易日下跌5.89%，主力资金累计净流入291.3万元；近20日主力资金累计净流入2710.5万元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211162248a6990daf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211162248a6990daf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09969","BK1161"],"gpt_icon":0},{"id":"2590560665","title":"国产创新药多点突破，抢滩1000亿美元规模炎症性肠病药物市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2590560665","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590560665?lang=zh_cn&edition=full","pubTime":"2025-12-11 11:25","pubTimestamp":1765423552,"startTime":"0","endTime":"0","summary":"有数据预测，到2032年全球IBD市场将达到1000亿美元规模。如云顶新耀引进的S1P调节剂伊曲莫德已在国内申报上市。资料显示，伊曲莫德作为一种新一代高选择性S1P受体调节剂，通过与S1P受体1、4和5结合，发挥调节免疫和炎症的作用。此外，匹康奇拜单抗200 mg组和600mg组达到症状缓解、内镜缓解或黏膜愈合的受试者比例均高于安慰剂组。目前评估Hemay005用于中度至重度溃疡性结肠炎的有效性的一项临床II期研究正在进行中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211112914a7311dcb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211112914a7311dcb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0502904849.HKD","LU2097828714.EUR","LU1969619763.USD","LU2097828805.USD","09969","LU2097828557.USD","LU2328871848.SGD","LU2488822045.USD","BK1583","06978","HK0000165453.HKD","LU2097828631.EUR","LU0455707207.USD","BK1161","LU2242644610.SGD","LU2097828474.EUR","BK1574","01801","BK1589"],"gpt_icon":0},{"id":"2590105213","title":"每日卖空追踪 | 诺诚健华 12月09日卖空量成交26.6万股，卖空比例为2.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590105213","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590105213?lang=zh_cn&edition=full","pubTime":"2025-12-09 16:30","pubTimestamp":1765269041,"startTime":"0","endTime":"0","summary":"诺诚健华北京时间12月09日，跌3.99%，卖空量成交26.6万股，较上一交易日减少61.05%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209163658979827b5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209163658979827b5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","BK1161","BK1574"],"gpt_icon":0},{"id":"2590031058","title":"诺诚健华12月09日主力净流出1300.9万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2590031058","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590031058?lang=zh_cn&edition=full","pubTime":"2025-12-09 16:15","pubTimestamp":1765268127,"startTime":"0","endTime":"0","summary":"12月09日, 诺诚健华股价跌3.99%，报收13.70元，成交金额1.4亿元，换手率0.69%，振幅6.59%，量比1.98。诺诚健华今日主力资金净流出1300.9万元，上一交易日主力净流入656.0万元。该股近5个交易日下跌3.59%，主力资金累计净流出275.8万元；近20日主力资金累计净流入2870.7万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209161721a43d3551&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209161721a43d3551&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","09969"],"gpt_icon":0},{"id":"2590510310","title":"诺诚健华新型BCL2抑制剂Mesutoclax最新临床数据闪耀第67届美国血液学会（ASH）年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2590510310","media":"制药在线","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590510310?lang=zh_cn&edition=full","pubTime":"2025-12-09 11:00","pubTimestamp":1765249217,"startTime":"0","endTime":"0","summary":"2025年12月9日，生物医药高科技公司诺诚健华今天宣布，公司自主研发的新型BCL2抑制剂mesutoclax共有三项研究在第67届美国血液学会年会上进行了公布。Mesutoclax治疗复发/难治性MCL的研究入选口头报告，mesutoclax治疗CLL/SLL和AML的两项研究入选海报展示。无论在初治CLL/SLL还是复发/难治性 CLL/SLL患者中，125毫克mesutoclax剂量组的ORR均为100%。Mesutoclax单药或联合奥布替尼治疗都展现了良好的安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209110021a43ca5a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209110021a43ca5a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09969","BK1574"],"gpt_icon":0}],"profile":{"websiteUrl":"https://cn.innocarepharma.com","stockEarnings":[{"period":"1week","weight":-0.0512},{"period":"1month","weight":-0.0726},{"period":"3month","weight":-0.1764},{"period":"6month","weight":0.0464},{"period":"1year","weight":1.2343},{"period":"ytd","weight":1.2124}],"compareEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0054},{"period":"3month","weight":-0.0322},{"period":"6month","weight":0.0918},{"period":"1year","weight":0.3006},{"period":"ytd","weight":0.2807}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"诺诚健华医药有限公司是一家主要从事生物医药研发、生产和商业化的中国公司。该公司专注于肿瘤和自身免疫性疾病等存在巨大未满足临床需求的领域。该公司的主要产品管线包括奥布替尼、Tafasitamab、ICP-490、ICP-B02、ICP-248、ICP-B05、ICP-332、ICP-488、ICP-192、ICP-723、ICP-033和ICP-189等。其产品主要用于治疗血液瘤、实体瘤和自身免疫病。该公司还在开发用于治疗由B细胞或T细胞功能异常所导致的自身免疫性疾病的产品。该公司主要在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.115368},{"month":2,"riseRate":0.6,"avgChangeRate":0.148393},{"month":3,"riseRate":0,"avgChangeRate":-0.036551},{"month":4,"riseRate":0.666667,"avgChangeRate":0.116223},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.042592},{"month":6,"riseRate":0.833333,"avgChangeRate":0.12939},{"month":7,"riseRate":0.5,"avgChangeRate":0.039258},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.082108},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.024907},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.033299},{"month":11,"riseRate":0.833333,"avgChangeRate":0.100833},{"month":12,"riseRate":0.5,"avgChangeRate":0.0013}],"exchange":"SEHK","name":"诺诚健华","nameEN":"INNOCARE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,09969,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}